# NeuroPace Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/NeuroPace Inc). ## Overview NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System. The company designs, manufactures, and sells a brain-responsive neuromodulation platform that monitors electrical activity in the brain and delivers targeted stimulation at the seizure source. ## Products & services • RNS System implantable neurostimulator • Brain-responsive seizure detection and therapy • Remote patient monitoring and clinician data access • Replacement procedures and device servicing • DIXI Medical products during wind-down period • Collaboration services - **RNS System** (85%) — Implantable brain-responsive neuromodulation devices and related therapy for epilepsy. - **Replacement procedures** (8%) — Sales tied to replacement of implanted RNS devices at end of service life. - **DIXI Medical products** (5%) — Adjunct epilepsy-related products sold to the existing customer base during wind-down. - **Services and collaboration revenue** (2%) — Service revenue and collaboration-related services, including work for partners. - RNS System implantable neurostimulator - Brain-responsive seizure detection and therapy - Remote patient monitoring and clinician data access - Replacement procedures and device servicing - DIXI Medical products during wind-down period - Collaboration services ## Customers NeuroPace sells primarily to hospital facilities that implant the RNS System for patients with drug-resistant epilepsy. The key users and influencers are epileptologists, neurosurgeons, and epilepsy centers that evaluate candidates, perform implantation, and manage follow-up care. A smaller portion of activity comes from related product sales to the existing customer base and collaboration services. - **Hospital facilities** (primary) — Buy RNS Systems for initial implants and replacement procedures for eligible epilepsy patients. - **Comprehensive epilepsy centers** (primary) — Evaluate, refer, and implant patients; they are the main channel for adoption and utilization. - **Physicians and specialists** (primary) — Epileptologists and neurosurgeons influence prescribing, implantation, and follow-up care. - **Existing installed base** (secondary) — Patients returning for replacement procedures as devices reach end of service. - **Partner customers** (emerging) — Counterparties receiving collaboration services and limited DIXI-related products. - Hospital facilities that purchase RNS Systems for implantation - Epileptologists who diagnose and prescribe therapy - Neurosurgeons who implant and manage the device - Comprehensive epilepsy centers that coordinate treatment pathways - Existing customers buying DIXI Medical products - Partner/collaboration counterparties buying services ## Geography NeuroPace is primarily a U.S. business, with nearly all revenue generated in the United States. The company also has limited sales in Canada under a special approval program, and it manufactures and distributes products from its Mountain View, California facility. - **United States** (99.5%) — Nearly all revenue is generated in the United States. - **Canada** (0.5%) — Limited sales under a special program with case-by-case approvals. - United States is the core commercial market - Nearly all revenue is generated in the U.S. - Limited sales in Canada under special approvals - Manufacturing and distribution are based in Mountain View, California - U.S. epilepsy centers drive most commercial activity ## Strategy NeuroPace is focused on expanding adoption of the RNS System across comprehensive epilepsy centers and broader referral pathways in the United States. Its strategy also includes clinical studies, regulatory work to support indication expansion, and continued development of future neuromodulation products. - **Expand U.S. commercial footprint** (short-term) — Adoption depends on physician awareness, referrals, and center-level penetration. - **Pursue indication expansion** (medium-term) — Broader labels can enlarge the addressable epilepsy population and support long-term growth. - **Build clinical evidence and data advantage** (medium-term) — Long-term outcomes and continuous brain data support physician adoption and differentiation. - **Develop future neuromodulation products** (long-term) — New products can extend the platform beyond the current epilepsy indication. - Expand adoption across Level 4 comprehensive epilepsy centers - Broaden referral pathways to bring more patients into care - Support indication expansion through clinical studies and FDA work - Invest in sales and marketing to build physician awareness - Develop future products for neurological disorders - Maintain optionality for acquisitions or technology investments ## Risks NeuroPace depends heavily on a single commercial product and a narrow U.S. epilepsy indication, so adoption, reimbursement, and physician preference are central to performance. The company also faces competition from larger neuromodulation manufacturers, regulatory dependence on FDA approvals, and operational exposure tied to manufacturing, cybersecurity, and data privacy. - **Dependence on a single product and indication** [high] — Most revenue comes from the RNS System for adults with drug-resistant focal epilepsy. - **Competitive pressure from larger device makers** [high] — LivaNova and Medtronic have greater scale, resources, and market presence. - **Regulatory and clinical adoption risk** [high] — Growth depends on FDA approvals, clinical evidence, and physician acceptance. - **Manufacturing and supply continuity** [medium] — Devices are manufactured and distributed from a single California facility. - **Cybersecurity and patient-data privacy** [medium] — The business handles sensitive health data and relies on connected systems and third parties. - Heavy reliance on the RNS System as the main revenue source - Narrow current label limits the addressable patient population - Competition from larger neuromodulation device makers - Adoption depends on physician awareness and reimbursement support - Manufacturing and supply chain disruptions could affect delivery - Cybersecurity and health-data privacy risks are material ## Accounting Revenue is driven by device sales, replacement procedures, service revenue, and limited collaboration or DIXI-related sales, so mix changes can affect period-to-period comparability. Investors should watch inventory reserves, product mix between initial and replacement implants, and the timing of collaboration and service revenue, all of which can move reported margins and revenue recognition patterns. - **Revenue recognition by product and service type** — Affects quarterly revenue comparability and mix analysis - **Product mix and replacement cycle** — Can create quarter-to-quarter variability in revenue and gross margin - **Inventory excess and obsolescence reserves** — Can materially affect cost of goods sold and gross profit - **Stock-based compensation and financing transactions** — Affects operating expense presentation and dilution analysis - Revenue mix shifts between initial implants and replacements - Service and collaboration revenue can vary with timing of work performed - DIXI Medical wind-down may create temporary mix and margin volatility - Inventory excess and obsolescence reserves are a key estimate - Single-facility manufacturing raises concentration in inventory and fixed assets - Debt, equity issuance, and stock-based compensation affect capital structure --- *Last updated: 2026-04-29T04:41:17.690753+00:00*